DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb for a Novel Cancer Target Discovery (NCTI) Initiative
DarwinHealth, a New York City-based biotechnology company, today announced a scientific research collaboration with Bristol-Myers Squibb Company (NYSE: BMY). The research collaboration, the Novel Cancer Target Initiative (NCTI), employs quantitative systems biology-based algorithms, proprietary databases, and validated technologies to identify novel cancer targets (NCTs) across a range of tumor subtypes. The methodology underpinning the NCTI is…